Search the Newsreel

BridgeBio Pharma, Inc. Stock 12‑Month Price Target Raised to $109.44, Implies 29% Upside

BridgeBio Pharma, Inc.'s stock (BBIO) has seen its average 12-month price target raised from $107.65 to $109.18 by 19 analysts, implying a potential 29% upside from its Aug. 10 closing price. The consensus rating for BBIO remains a "Buy" among 23 analysts, with 21 …

BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months (NASDAQ:BBIO)

BridgeBio Pharma reported strong Q2 results, exceeding analyst expectations and reaffirming its guidance for Attruby/Beyonttra global sales to surpass $1 billion this year. The company saw a significant surge in Attruby's U.S. net sales and increased Beyonttra royalties, indicating growing market share. BridgeBio's recent …

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BridgeBio Pharma (BBIO) reported a wider-than-expected Q2 2026 loss of 78 cents per share but saw revenues surge 120% year over year to $243.7 million, beating estimates, primarily driven by strong sales of its drug Attruby. The company is also advancing multiple late-stage pipeline …

Enbridge Inc. stock rises Tuesday, outperforms market

Enbridge Inc. (ENB) stock increased by 0.20% on Tuesday, closing at C$71.85, outperforming the S&P/TSX Composite Index which rose 0.05%. The company's stock is currently 10.9% below its 52-week high of C$80.65, achieved on May 22nd.

BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, TD Cowen Analyst Says

Morgan Stanley Has Lowered Expectations for BridgeBio Pharma (NASDAQ:BBIO) Stock Price

Corebridge Financial (NYSE:CRBG) Shares Gap Down - Here's Why

Chain Bridge Bancorp (CBNA) lifts profit with strong capital and high liquidity

BRIDGEBIO PHARMA, INC. : TRUIST SECURITIES RAISES TARGET PRICE TO $107 FROM $102

Truist Securities has increased its target price for BridgeBio Pharma, Inc. (BBIO.O) from $102 to $107. The news was reported by Reuters. This adjustment reflects an updated outlook on the company's valuation by the financial institution.

Wells Fargo raises BridgeBio Pharma stock price target on launch outlook

Wells Fargo has increased its price target for BridgeBio Pharma (NASDAQ:BBIO) to $102 from $98, maintaining an Overweight rating due to anticipated near-term launches. Despite an 11% year-to-date gain, the stock is considered slightly overvalued. The firm expects further upside after detailed CARDIO-Transform data …

Enbridge's Profit Just Fell 7%. Here's Why That's Not the Real Story.

Midstream operator Enbridge (NYSE: ENB) reported earnings on July 31, and its stock has tumbled more than 7% since. The reason was obvious. The company's profit margin narrowed because its heavy debt load is weighing on net earnings. Enbridge reported earnings per share (EPS) …

Clearbridge Health Reconstitutes Board Following Director’s Cessation

Noida Toll Bridge Company Ltd is Rated Sell

Quantinno Capital Management LP Purchases 21,464 Shares of BridgeBio Pharma, Inc. $BBIO

Quantinno Capital Management LP significantly increased its stake in BridgeBio Pharma, Inc. by 199.2% in the first quarter, adding 21,464 shares to reach a total of 32,240 shares valued at $2.39 million. This move is part of broader institutional investment, with firms like Janus …

Clearbridge Health Limited Announces Cessation of Yee Pinh Jeremy as Non-Executive Non-Independent Director, Effective August 25, 2026

Chain Bridge Bancorp (CBNA) Edges Higher: Modest Gains Amid Narrow Trading Range - Impulse Wave

Oxley Bridge Acquisition Ord Shs Class A (OBA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Oxley Bridge Acquisition Ord Shs Class A (OBA), detailing future EPS and revenue growth estimates. It includes current stock information such as market cap, P/E ratio, and recent stock price movements. The forecast section covers expected EPS, …

BridgeBio Pharma Inc (BBIO) (Q2 2026) Earnings Call Highlights: Attruby Surges 211% as Pipeline ...

This article first appeared on GuruFocus. Total Revenues: $243.7 million for Q2 2026, compared to $110.6 million in Q2 2025. Attruby Net Product Revenue: $222.4 million, up from $71.5 million in the same period last year. Royalty Revenue: Increased to $15.4 million from $1.6 …

BridgeBio outlines three launches with first PDUFA set for November 27, 2026 and RECLAIM-HP readout in next 18 months

Earnings Call Insights: BridgeBio Pharma (BBIO) Q2 2026 MANAGEMENT VIEW * CEO Neil Kumar framed Q2 as a turning point, saying, "it feels like we're at T=0 in BridgeBio's next chapter," and tied near-term value creation to Attruby’s next phase, adding, "the combination of …

LandBridge Company LLC Class A Revenue Breakdown – TRADEGATE:D5O

LandBridge Company LLC Class A (TRADEGATE:D5O) reported significant revenue in the last fiscal year, totaling ‪169.51 M‬ EUR. The primary revenue driver was the Surface Use Royalties segment, which generated ‪61.96 M‬ EUR, a substantial increase from the previous year. The United States was …

CRBG Looks 4.5% Undervalued on GF Value™

Corebridge Financial Inc (NYSE: CRBG) appears 4.5% undervalued according to GuruFocus' GF Value™, despite recent insider selling. Morgan Stanley's appointment as book-running manager for a recent offering signals market confidence, while the company offers an attractive and sustainable dividend yield of 2.84% with a …

Insider Selling: Bridgewater Bancshares (NASDAQ:BWB) Director Sells $850,400.00 in Stock

BridgeBio Pharma (NASDAQ:BBIO) Announces Earnings Results

Bridgewater Bancshares (BWB) director Shellberg sells 40,000 common shares at $21.26

I Compared Enbridge and Suncor: Here’s My Pick This Year

This article compares two Canadian energy companies, Enbridge (TSX:ENB) and Suncor Energy (TSX:SU), for long-term investors focused on dividends and growth. While Suncor offers a cheaper valuation and potential for appreciation, the author picks Enbridge due to its steadier, utility-like cash flow, higher dividend …

BridgeBio Pharma (NASDAQ: BBIO) grows Q2 2026 revenue but carries heavy debt load

BRIDGEBIO PHARMA ($BBIO) Releases Q2 2026 Earnings

This article first appeared on GuruFocus. Total Revenues: $243.7 million for Q2 2026, compared to $110.6 million in Q2 2025. Attruby Net Product Revenue: $222.4 million, up from $71.5 million in the same period last year. Royalty Revenue: Increased to $15.4 million from $1.6 …

BridgeBio Pharma 2026: Revenue $243.68M, EPS ($0.78) — 10-Q Summary

BridgeBio Pharma reported its 2026 quarterly results, showing a significant increase in revenue to $243.68M from $110.57M in the prior year. Despite the revenue growth, the company recorded a net loss of ($152.22M) and a diluted loss per share of ($0.78), though these figures …

Earnings Flash (BBIO) BridgeBio Pharma, Inc. Reports Q2 Revenue $243.7M, vs. FactSet Est of $220.9M

BridgeBio Pharma, Inc. (BBIO) reported its Q2 revenue of $243.7 million, surpassing the FactSet estimate of $220.9 million. The company's stock, traded on Nasdaq, saw a slight increase of 0.22% on August 10, 2026, with year-to-date growth of 10.69%. BridgeBio Pharma focuses on developing …

BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates

BridgeBio Pharma, Inc. - $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep patients on Attruby - Attruby is the first ATTR-CM …

Corebridge Financial (CRBG) Is Up 7.6% After Q2 Profit, Capital Returns And Annuity Expansion

Corebridge Financial (CRBG) saw its stock rise 7.6% after reporting a Q2 profit, completing a significant share repurchase program, and declaring a common dividend. The company also expanded its Power Series of Index Annuities to enhance retirement product offerings. These developments reinforce Corebridge's focus …

BridgeBio Pharma earnings up next amid encaleret milestone

BridgeBio Pharma is set to report its second-quarter earnings, with analysts expecting a loss of 60 cents per share on revenues of $222.2 million, driven by strong Attruby sales. Investors are keenly watching the commercial performance and the regulatory progress of encaleret, its experimental …

BridgeBio Pharma: Q2 Earnings Snapshot

BridgeBio Pharma Inc. reported a Q2 loss of $152.2 million, or 78 cents per share, missing analyst expectations of 64 cents per share. Despite the loss, the rare disease drug developer exceeded revenue forecasts, posting $243.7 million against an expected $222.6 million. The company's …

DigitalBridge: Strong Earnings, But The Upside Is Capped (NYSE:DBRG)

Bridgestone (TSE:5108) Posts Strong H1 Results, Is The Rally Already Priced In?

Bridgewater Bancshares (BWB) Stock Fair Value Rises After Analysts Lift Earnings Outlook

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. The fair value estimate for Bridgewater Bancshares has shifted from US$22.13 to US$24.00, pointing to an updated long term price target in the mid US$20s. …